Efficacy and safety of combined TACE-HAIC and targeted immunotherapy in primary liver cancer with portal vein tumor thrombus - Top-Institutions - MDSpire

Efficacy and safety of combined TACE-HAIC and targeted immunotherapy in primary liver cancer with portal vein tumor thrombus

  • By

  • Shaoqin Yang

  • Shuangshuang Zhang

  • Yuming Gu

  • June 15, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Zhongda Hospital, Medical School, Southeast University
    Zhongda Hospital, Medical School, Southeast University

    Nanjing, Jiangsu

    Key Differentiators

    • Hepatology

  • #2

    Affiliated Hospital of Xuzhou Medical University
    Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu

    Key Differentiators

    • Hepatology

  • #3

    Hunan Provincial People’s Hospital
    Hunan Provincial People’s Hospital

    Changsha, Hunan

    Key Differentiators

    • Hepatology

Original Source(s)

Efficacy and safety of combined TACE-HAIC and targeted immunotherapy in primary liver cancer with portal vein tumor thrombus

  • by Shaoqin Yang, Shuangshuang Zhang, Yuming Gu

  • June 15, 2026

Related Content

Case Report: Pediatric nasopharyngeal carcinoma masquerading as benign lymphadenopathy: diagnostic pitfalls in two cases

An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy

Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features